iX Biopharma’s Trial Boosts NAD+ and Wellness

iX Biopharma Ltd. (SG:42C) has released an update.

iX Biopharma Ltd has reported successful results from a human trial of its SL-NAD+ sublingual wafers, showing a significant increase in blood NAD+ levels, up to 76% over six weeks, and improvements in energy, mood, sleep, mental clarity, and physical strength. The trial, which underscores the potential of NAD+ supplementation for enhancing quality of life, also confirmed the wafers to be safe and well tolerated. The company highlights the product’s superior delivery method and bioavailability as a convenient and effective way to maintain optimal NAD+ levels for healthspan.

For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.